Point72 DIFC Ltd Acquires 1,715 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Point72 DIFC Ltd increased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 9.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,255 shares of the company’s stock after acquiring an additional 1,715 shares during the quarter. Point72 DIFC Ltd’s holdings in Keros Therapeutics were worth $1,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. KBC Group NV increased its stake in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics in the 2nd quarter worth about $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the 3rd quarter worth about $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Up 8.8 %

Shares of NASDAQ KROS opened at $67.79 on Thursday. The firm’s 50-day moving average price is $59.89 and its 200-day moving average price is $52.48. The company has a market cap of $2.75 billion, a PE ratio of -13.01 and a beta of 1.20. Keros Therapeutics, Inc. has a 52-week low of $27.31 and a 52-week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) earnings per share. As a group, equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Bank of America reduced their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Guggenheim restated a “buy” rating on shares of Keros Therapeutics in a research note on Wednesday. Finally, Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.